HRP20041177B1 - Mikrobicidni pirimidini ili triazini za prevenciju prijenosa hiv seksualnim putem - Google Patents
Mikrobicidni pirimidini ili triazini za prevenciju prijenosa hiv seksualnim putemInfo
- Publication number
- HRP20041177B1 HRP20041177B1 HRP20041177AA HRP20041177A HRP20041177B1 HR P20041177 B1 HRP20041177 B1 HR P20041177B1 HR P20041177A A HRP20041177A A HR P20041177AA HR P20041177 A HRP20041177 A HR P20041177A HR P20041177 B1 HRP20041177 B1 HR P20041177B1
- Authority
- HR
- Croatia
- Prior art keywords
- triazine
- hiv transmission
- present
- preventing sexual
- microbicidal
- Prior art date
Links
- 230000003641 microbiacidal effect Effects 0.000 title abstract 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 230000005540 biological transmission Effects 0.000 title 1
- 230000001568 sexual effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 abstract 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 230000005582 sexual transmission Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 150000003918 triazines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Abstract
Ovaj izum odnosi se na mikrobicidnu aktivnost određenih pirimidina ili triazina koji sadrže nenukleozidne reverzne transkriptaza inhibitore. Spojevi ovog izuma inhibiraju sistemsku infekciju kod ljudi zaraženih virusom HIV, posebice, spojevi ovog izuma sprječavaju prijenos HIV seksualnim putem kod ljudi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02076897 | 2002-05-13 | ||
PCT/EP2003/050158 WO2003094920A1 (en) | 2002-05-13 | 2003-05-13 | Microbicidal pyrimidine or triazine for preventing sexual hiv transmission |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20041177A2 HRP20041177A2 (hr) | 2006-04-30 |
HRP20041177B1 true HRP20041177B1 (hr) | 2013-03-31 |
Family
ID=29414777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20041177AA HRP20041177B1 (hr) | 2002-05-13 | 2004-12-10 | Mikrobicidni pirimidini ili triazini za prevenciju prijenosa hiv seksualnim putem |
Country Status (27)
Country | Link |
---|---|
US (4) | US7935710B2 (hr) |
EP (1) | EP1505980B1 (hr) |
JP (2) | JP4530848B2 (hr) |
KR (1) | KR101095358B1 (hr) |
CN (2) | CN1668305B (hr) |
AP (1) | AP2024A (hr) |
AR (1) | AR039540A1 (hr) |
AT (1) | ATE376420T1 (hr) |
AU (1) | AU2003240844B2 (hr) |
BR (2) | BR122014006936B8 (hr) |
CA (1) | CA2486078C (hr) |
CY (1) | CY1110249T1 (hr) |
DE (1) | DE60317060T2 (hr) |
DK (1) | DK1505980T3 (hr) |
EA (1) | EA011298B1 (hr) |
ES (1) | ES2294291T3 (hr) |
HK (1) | HK1173141A1 (hr) |
HR (1) | HRP20041177B1 (hr) |
IL (1) | IL165174A (hr) |
MX (1) | MXPA04011392A (hr) |
NO (2) | NO331030B1 (hr) |
NZ (1) | NZ536976A (hr) |
PL (1) | PL215128B1 (hr) |
PT (1) | PT1505980E (hr) |
SI (1) | SI1505980T1 (hr) |
WO (1) | WO2003094920A1 (hr) |
ZA (1) | ZA200409984B (hr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
EP1597237B1 (en) | 2003-02-07 | 2016-07-27 | Janssen Pharmaceutica NV | Pyrimidine derivatives for the prevention of HIV infection |
CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
ITMI20031640A1 (it) | 2003-08-08 | 2005-02-09 | Mipharm S P A | Base per gel bioadesivi. |
UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
JP5247154B2 (ja) * | 2005-02-18 | 2013-07-24 | テイボテク・フアーマシユーチカルズ | Hiv阻害性2−(4−シアノフェニルアミノ)ピリミジンオキシド誘導体 |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2007071199A1 (fr) * | 2005-12-22 | 2007-06-28 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Composes de 2,4-disubstituee amido-6-substituee-[1,3,5]triazine ou de 1,3-pyrimidine, leurs procedes d'elaboration, et preparations pharmaceutiques les contenant et leurs utilisations |
CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2007146981A2 (en) | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
MX2008016007A (es) | 2006-06-15 | 2009-01-16 | Boehringer Ingelheim Int | 2-anilino-4-aminoalquilenoaminopirimidinas. |
EP3012249A1 (en) | 2006-12-08 | 2016-04-27 | Novartis AG | Compounds and composition as protein kinase inhibitors |
JP5415957B2 (ja) * | 2006-12-13 | 2014-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としての2−(ピペリジン−4−イル)−4−フェノキシ−又はフェニルアミノ−ピリミジン誘導体 |
CA2674178C (en) * | 2006-12-29 | 2015-11-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 6-substituted pyrimidines |
AU2007341228B2 (en) * | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
EP2214486A4 (en) | 2007-10-19 | 2011-03-09 | Avila Therapeutics Inc | HETEROARYL COMPOUNDS AND ITS USES |
CA2723961C (en) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
HUE046617T2 (hu) | 2010-11-10 | 2020-03-30 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
US10426761B2 (en) | 2011-04-19 | 2019-10-01 | Arms Pharmaceutical, Llc | Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof |
US20130039959A1 (en) * | 2011-04-19 | 2013-02-14 | Brian Vincent Sokol | Method of inhibiting hiv and barrier-forming composition therefor |
CN103619341A (zh) | 2011-04-19 | 2014-03-05 | Arms制药有限公司 | 抑制有害微生物的方法及其阻隔形成组合物 |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
CN102675212B (zh) * | 2012-05-09 | 2014-11-05 | 昆明理工大学 | N-取代苯基-2-((1h-苯并咪唑-2-基)巯基)乙酰胺类衍生物及其用途 |
CA2891412A1 (en) | 2012-11-20 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
JP6466107B2 (ja) * | 2014-09-04 | 2019-02-06 | 東ソー・ファインケム株式会社 | 4−フェニルチオ−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法 |
CN105085410B (zh) * | 2015-08-21 | 2017-10-10 | 武汉工程大学 | 一种二芳基嘧啶类hiv‑1抑制剂及其制备方法 |
EP3370701A1 (en) | 2015-11-06 | 2018-09-12 | INEB-Instituto Nacional De Engenharia Biomédica | A composition for use in a method for prevention or treatment of human immunodeficiency virus infections |
CN106478521A (zh) * | 2016-10-11 | 2017-03-08 | 武汉工程大学 | 一种二芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法 |
CN106866628A (zh) * | 2017-02-27 | 2017-06-20 | 武汉工程大学 | 一种芳基杂芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法 |
CA3060416A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
CN109053613A (zh) * | 2018-07-04 | 2018-12-21 | 复旦大学 | 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途 |
BR112021006553A2 (pt) | 2018-12-04 | 2021-07-13 | Virox Technologies Inc. | composições antimicrobianas contendo c3-c5 n-alquil-gama-butirolactama e usos dos mesmos |
US20220033851A1 (en) * | 2020-08-03 | 2022-02-03 | Roger B. Swartz | mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A. |
AU2022323509A1 (en) | 2021-08-03 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
WO2023220645A1 (en) | 2022-05-10 | 2023-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vaccine for human t-lymphotropic virus-1 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050256A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections |
WO1999050250A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
WO2000027825A1 (en) * | 1998-11-10 | 2000-05-18 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines |
WO2000027828A2 (en) * | 1998-11-10 | 2000-05-18 | Janssen Pharmaceutica N.V. | 2,4-disubstituted triazine derivatives with anti hiv activity |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4983393A (en) * | 1987-07-21 | 1991-01-08 | Maximed Corporation | Intra-vaginal device and method for sustained drug release |
ES2010091A6 (es) | 1988-01-20 | 1989-10-16 | Univ Minnesota | Un metodo para preparar compuestos analogos a nucleosidos didesoxicarbociclicos. |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
JPH075465B2 (ja) | 1990-03-29 | 1995-01-25 | 三菱化学株式会社 | 抗ウイルス剤 |
JP3094036B2 (ja) * | 1990-07-19 | 2000-10-03 | ザ ウエルカム ファウンデーション リミテッド | 酵素不活性化剤 |
GB9214720D0 (en) * | 1992-07-10 | 1992-08-19 | Wellcome Found | Enzyme inhibitors |
NZ273741A (en) * | 1993-08-24 | 2000-06-23 | Medivir Ab | Heterocyclically-substituted guanidine, urea and thiourea derivatives |
US6165493A (en) | 1997-10-22 | 2000-12-26 | New York Blood Center, Inc. | "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections" |
US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
CN1353573A (zh) * | 1999-05-14 | 2002-06-12 | 加利福尼亚大学董事会 | 对炎症介导感染的抗炎症治疗 |
EA005423B1 (ru) | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
KR20030032947A (ko) | 2000-05-05 | 2003-04-26 | 에프. 호프만-라 로슈 아게 | 센티널 바이러스 ⅱ |
DK1282607T3 (en) | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
ES2542326T3 (es) * | 2000-05-08 | 2015-08-04 | Janssen Pharmaceutica Nv | Inhibidores de la replicación del VIH |
US6596729B2 (en) * | 2000-07-20 | 2003-07-22 | Bristol-Myers Squibb Company | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
CN1494528A (zh) * | 2001-03-02 | 2004-05-05 | ʷ��˿�������ȳ�ķ����˾ | 作为逆转录酶抑制剂的二苯酮 |
CN1536986B (zh) | 2001-03-27 | 2012-07-04 | 沃纳奇尔科特(爱尔兰)有限公司 | 用于抗微生物剂给药的***内药物递送装置 |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
TW200306192A (en) | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
-
2003
- 2003-05-12 AR ARP030101642A patent/AR039540A1/es not_active Application Discontinuation
- 2003-05-13 DK DK03730208T patent/DK1505980T3/da active
- 2003-05-13 AU AU2003240844A patent/AU2003240844B2/en not_active Expired
- 2003-05-13 WO PCT/EP2003/050158 patent/WO2003094920A1/en active IP Right Grant
- 2003-05-13 KR KR1020047018312A patent/KR101095358B1/ko active IP Right Grant
- 2003-05-13 SI SI200331043T patent/SI1505980T1/sl unknown
- 2003-05-13 JP JP2004503005A patent/JP4530848B2/ja not_active Expired - Lifetime
- 2003-05-13 US US10/514,361 patent/US7935710B2/en active Active
- 2003-05-13 ES ES03730208T patent/ES2294291T3/es not_active Expired - Lifetime
- 2003-05-13 MX MXPA04011392A patent/MXPA04011392A/es active IP Right Grant
- 2003-05-13 BR BR122014006936A patent/BR122014006936B8/pt active IP Right Grant
- 2003-05-13 CA CA2486078A patent/CA2486078C/en not_active Expired - Lifetime
- 2003-05-13 PT PT03730208T patent/PT1505980E/pt unknown
- 2003-05-13 DE DE60317060T patent/DE60317060T2/de not_active Expired - Lifetime
- 2003-05-13 EA EA200401494A patent/EA011298B1/ru unknown
- 2003-05-13 AP AP2004003182A patent/AP2024A/xx active
- 2003-05-13 EP EP03730208A patent/EP1505980B1/en not_active Expired - Lifetime
- 2003-05-13 AT AT03730208T patent/ATE376420T1/de active
- 2003-05-13 CN CN038163594A patent/CN1668305B/zh not_active Expired - Lifetime
- 2003-05-13 NZ NZ536976A patent/NZ536976A/en not_active IP Right Cessation
- 2003-05-13 CN CN201110374093.0A patent/CN102558070B/zh not_active Expired - Lifetime
- 2003-05-13 PL PL373840A patent/PL215128B1/pl unknown
- 2003-05-13 BR BRPI0310021A patent/BRPI0310021B8/pt not_active IP Right Cessation
-
2004
- 2004-11-11 IL IL165174A patent/IL165174A/en active IP Right Grant
- 2004-12-01 NO NO20045267A patent/NO331030B1/no not_active IP Right Cessation
- 2004-12-09 ZA ZA200409984A patent/ZA200409984B/xx unknown
- 2004-12-10 HR HRP20041177AA patent/HRP20041177B1/hr not_active IP Right Cessation
-
2008
- 2008-01-22 CY CY20081100084T patent/CY1110249T1/el unknown
-
2010
- 2010-05-07 JP JP2010107209A patent/JP5256244B2/ja not_active Expired - Lifetime
-
2011
- 2011-02-22 NO NO20110298A patent/NO334067B1/no not_active IP Right Cessation
- 2011-03-08 US US13/043,174 patent/US20110165093A1/en not_active Abandoned
-
2013
- 2013-01-07 HK HK13100210.9A patent/HK1173141A1/zh not_active IP Right Cessation
-
2016
- 2016-12-23 US US15/389,662 patent/US20170100399A1/en not_active Abandoned
-
2020
- 2020-07-16 US US16/930,581 patent/US20200345733A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050256A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections |
WO1999050250A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
WO2000027825A1 (en) * | 1998-11-10 | 2000-05-18 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines |
WO2000027828A2 (en) * | 1998-11-10 | 2000-05-18 | Janssen Pharmaceutica N.V. | 2,4-disubstituted triazine derivatives with anti hiv activity |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20041177B1 (hr) | Mikrobicidni pirimidini ili triazini za prevenciju prijenosa hiv seksualnim putem | |
DE69909756D1 (de) | Antivirale pyrimidinderivate | |
ATE451914T1 (de) | Dispergierbare bosertan-tablette | |
BR0309557A (pt) | Inibidores da transcriptase reversa não nucleosìdeos | |
ATE361915T1 (de) | Die hiv-replikation inhibierende pyrimidine und triazine | |
CY2012012I2 (el) | Παραγωγα πυριμιδινης που αναστελλουν τον hiv | |
NO20034836D0 (no) | Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF) | |
DE602007009508D1 (de) | Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine | |
DK1171137T3 (da) | Anvendelse af triacetyluridin til behandling af mitochondriale lidelser | |
DE60316468D1 (de) | Pyrimidine verbindungen | |
DK1401501T3 (da) | Orale farmaceutiske sammensætninger med modificeret frigivelse af den aktive ingrediens | |
NO20051082L (no) | Antimikrobielle kinoloner, deres sammensetninger og anvendelser | |
CR8451A (es) | Uso de derivados de n-arilhidracina para combatir pestes | |
EA200702169A1 (ru) | Профилактика вич-инфекции | |
MY169670A (en) | Combinations of a pyrimidine containing nnrti with rt inhibitors | |
BRPI0516242A (pt) | compostos tieno-pirimidina tendo atividade fungicida | |
BRPI0512547A (pt) | pirimidinas | |
YU102503A (sh) | Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva | |
MD20080028A (en) | Herbicidal composition | |
EA200601176A1 (ru) | 3-цианохинолиновые производные с антипролиферативной активностью | |
DK1066854T3 (da) | Anthelmintiske kompositioner indeholdende kombinationer af avermectiner eller milbemyciner med bis-aryl forbindelser | |
SE0301654D0 (sv) | Novel compounds | |
UY29707A1 (es) | Compuestos de 7-amino-6-heteroaril-1,2,4-triazolo(1,5-a)pirimidina y su empleo para combatir hongos daninos | |
SE0100733D0 (sv) | Non-nucleoside reverse transcriptase inhibitors | |
DK1305296T3 (da) | 5-substituerede pyrimidinderivater af konformationsfastlagte nucleosidanaloge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
PPPP | Transfer of rights |
Owner name: JANSSEN SCIENCES IRELAND UC, IE |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190417 Year of fee payment: 17 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200422 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210510 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20220504 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20230513 |